Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Vaxart ( (VXRT) ) has provided an update.
On July 8, 2025, Vaxart announced that its common stock has been approved to trade on the OTCQX Best Market, providing enhanced transparency and accessibility for investors. This move follows a delisting notice from Nasdaq, with Vaxart seeking a hearing to address the issue, while continuing to focus on advancing its oral pill vaccines for infectious diseases.
The most recent analyst rating on (VXRT) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Vaxart stock, see the VXRT Stock Forecast page.
Spark’s Take on VXRT Stock
According to Spark, TipRanks’ AI Analyst, VXRT is a Neutral.
The overall stock score is primarily influenced by Vaxart’s significant financial challenges, despite strong revenue growth. Technical indicators show bearish sentiment, and valuation concerns persist due to the negative P/E ratio. Positive corporate events and earnings call developments provide some upside, but risks remain elevated.
To see Spark’s full report on VXRT stock, click here.
More about Vaxart
Vaxart is a clinical-stage biotechnology company focused on developing oral recombinant vaccines using its proprietary delivery platform. The company aims to create vaccines that can be administered in pill form, eliminating the need for refrigeration and needle-stick injuries. Vaxart’s current development programs include vaccines for coronavirus, norovirus, influenza, and a therapeutic vaccine for HPV, marking its first venture into immune-oncology.
Average Trading Volume: 4,702,150
Technical Sentiment Signal: Sell
Current Market Cap: $73.06M
See more data about VXRT stock on TipRanks’ Stock Analysis page.